JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Structure Therapeutics (NASDAQ:GPCR) Stock

Structure Therapeutics (NASDAQ:GPCR) had its price target hoisted by research analysts at JPMorgan Chase & Co. from $65.00 to $105.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective would suggest a potential upside of 16.19% from the company’s previous close.

Several other equities analysts have also recently commented on the stock. BMO Capital Markets reaffirmed an “outperform” rating on shares of Structure Therapeutics in a research note on Tuesday, January 6th. Guggenheim boosted their price target on shares of Structure Therapeutics from $90.00 to $140.00 and gave the company a “buy” rating in a research report on Tuesday. Zacks Research cut shares of Structure Therapeutics from a “hold” rating to a “strong sell” rating in a report on Friday, October 17th. Morgan Stanley lifted their price objective on Structure Therapeutics from $120.00 to $125.00 and gave the company an “overweight” rating in a research note on Friday, December 12th. Finally, Piper Sandler restated an “overweight” rating on shares of Structure Therapeutics in a research note on Tuesday, October 28th. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Structure Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $104.45.

Structure Therapeutics Stock Performance

Shares of NASDAQ GPCR opened at $90.37 on Thursday. Structure Therapeutics has a fifty-two week low of $13.22 and a fifty-two week high of $94.90. The stock has a market cap of $5.48 billion, a PE ratio of -74.07 and a beta of -2.05. The stock has a fifty day moving average of $60.89 and a 200-day moving average of $36.51.

Structure Therapeutics (NASDAQ:GPCR) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.01). On average, sell-side analysts predict that Structure Therapeutics will post -0.82 EPS for the current year.

Hedge Funds Weigh In On Structure Therapeutics

A number of large investors have recently modified their holdings of the company. Balyasny Asset Management L.P. bought a new stake in Structure Therapeutics in the 3rd quarter worth approximately $12,923,000. Pacific Heights Asset Management LLC bought a new stake in shares of Structure Therapeutics in the 2nd quarter worth approximately $9,540,000. Orbimed Advisors LLC lifted its holdings in shares of Structure Therapeutics by 49.5% in the 2nd quarter. Orbimed Advisors LLC now owns 1,199,300 shares of the company’s stock worth $24,873,000 after acquiring an additional 397,272 shares during the last quarter. Paradigm Biocapital Advisors LP purchased a new stake in shares of Structure Therapeutics in the 3rd quarter valued at $10,440,000. Finally, Casdin Capital LLC grew its holdings in shares of Structure Therapeutics by 26.9% during the 3rd quarter. Casdin Capital LLC now owns 1,555,000 shares of the company’s stock valued at $43,540,000 after purchasing an additional 330,000 shares during the last quarter. 91.78% of the stock is owned by hedge funds and other institutional investors.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.